AIMS: Cardiac resynchronization therapy (CRT) improves echocardiographic parameters, symptoms, hospitalizations, and mortality in patients with New York Heart Association (NYHA) Class III or IV symptoms with left ventricular systolic dysfunction, sinus rhythm, and a prolonged QRS duration. The effectiveness of CRT in patients with mild heart failure symptoms has not been systematically reviewed. METHODS AND RESULTS: Randomized controlled trials of CRT in patients with NYHA Class I or II heart failure were identified from MEDLINE and EMBASE. The effects of CRT on left ventricular remodelling at 1 year were systematically reviewed, and the effects of CRT on clinical outcomes at 1 year were meta-analysed. Two studies met the pre-specified search criteria, with a total of 2430 patients (REVERSE n = 610 and MADIT-CRT n = 1820). CRT was associated with a reduction in heart failure events in both trials [combined OR 0.57, 95% confidence interval (CI) 0.46-0.70], but not mortality (combined OR 0.96, 95% CI 0.67-1.36). The effect of CRT on the combined endpoint of heart failure events or death favoured CRT (OR 0.63, 95% CI 0.51-0.77). CRT was also associated with improvement in left ventricular remodelling parameters in both studies, including a greater increase in left ventricular ejection fraction in the CRT group than in the control group, at 1 year after randomization. Serious adverse events were rare with CRT. CONCLUSION: CRT reduces heart failure events in patients with mild heart failure symptoms, left ventricular dysfunction, sinus rhythm, and prolonged QRS duration.
AIMS: Cardiac resynchronization therapy (CRT) improves echocardiographic parameters, symptoms, hospitalizations, and mortality in patients with New York Heart Association (NYHA) Class III or IV symptoms with left ventricular systolic dysfunction, sinus rhythm, and a prolonged QRS duration. The effectiveness of CRT in patients with mild heart failure symptoms has not been systematically reviewed. METHODS AND RESULTS: Randomized controlled trials of CRT in patients with NYHA Class I or II heart failure were identified from MEDLINE and EMBASE. The effects of CRT on left ventricular remodelling at 1 year were systematically reviewed, and the effects of CRT on clinical outcomes at 1 year were meta-analysed. Two studies met the pre-specified search criteria, with a total of 2430 patients (REVERSE n = 610 and MADIT-CRT n = 1820). CRT was associated with a reduction in heart failure events in both trials [combined OR 0.57, 95% confidence interval (CI) 0.46-0.70], but not mortality (combined OR 0.96, 95% CI 0.67-1.36). The effect of CRT on the combined endpoint of heart failure events or death favoured CRT (OR 0.63, 95% CI 0.51-0.77). CRT was also associated with improvement in left ventricular remodelling parameters in both studies, including a greater increase in left ventricular ejection fraction in the CRT group than in the control group, at 1 year after randomization. Serious adverse events were rare with CRT. CONCLUSION: CRT reduces heart failure events in patients with mild heart failure symptoms, left ventricular dysfunction, sinus rhythm, and prolonged QRS duration.
Authors: Sharon Ann Hunt; William T Abraham; Marshall H Chin; Arthur M Feldman; Gary S Francis; Theodore G Ganiats; Mariell Jessup; Marvin A Konstam; Donna M Mancini; Keith Michl; John A Oates; Peter S Rahko; Marc A Silver; Lynne Warner Stevenson; Clyde W Yancy Journal: J Am Coll Cardiol Date: 2009-04-14 Impact factor: 24.094
Authors: Dirk J van Veldhuisen; Alexander H Maass; Silvia G Priori; Pelle Stolt; Isabelle C van Gelder; Kenneth Dickstein; Karl Swedberg Journal: Eur J Heart Fail Date: 2009-11-01 Impact factor: 15.534
Authors: Rudolf Berger; Aparna Shankar; Friedrich Fruhwald; Astrid Fahrleitner-Pammer; Nick Freemantle; Luigi Tavazzi; John G F Cleland; Richard Pacher Journal: Eur Heart J Date: 2009-06-02 Impact factor: 29.983
Authors: Martin St John Sutton; Stefano Ghio; Ted Plappert; Luigi Tavazzi; Laura Scelsi; Claude Daubert; William T Abraham; Michael R Gold; Christian Hassager; John M Herre; Cecilia Linde Journal: Circulation Date: 2009-10-26 Impact factor: 29.690
Authors: Cecilia Linde; William T Abraham; Michael R Gold; Martin St John Sutton; Stefano Ghio; Claude Daubert Journal: J Am Coll Cardiol Date: 2008-11-07 Impact factor: 24.094
Authors: Claude Daubert; Michael R Gold; William T Abraham; Stefano Ghio; Christian Hassager; Grahame Goode; Tamás Szili-Török; Cecilia Linde Journal: J Am Coll Cardiol Date: 2009-10-01 Impact factor: 24.094
Authors: Arthur J Moss; W Jackson Hall; David S Cannom; Helmut Klein; Mary W Brown; James P Daubert; N A Mark Estes; Elyse Foster; Henry Greenberg; Steven L Higgins; Marc A Pfeffer; Scott D Solomon; David Wilber; Wojciech Zareba Journal: N Engl J Med Date: 2009-09-01 Impact factor: 91.245
Authors: George Wells; Ratika Parkash; Jeffrey S Healey; Mario Talajic; J Malcolm Arnold; Shannon Sullivan; Joan Peterson; Elizabeth Yetisir; Patricia Theoret-Patrick; Marilynn Luce; Anthony S L Tang Journal: CMAJ Date: 2011-01-31 Impact factor: 8.262
Authors: Pasquale Santangeli; Luigi Di Biase; Gemma Pelargonio; Antonio Dello Russo; Michela Casella; Stefano Bartoletti; J David Burkhardt; Prasant Mohanty; Pietro Santarelli; Andrea Natale Journal: J Interv Card Electrophysiol Date: 2011-05-19 Impact factor: 1.900
Authors: John Bourke; Cathy Turner; William Bradlow; Ashish Chikermane; Caroline Coats; Matthew Fenton; Maria Ilina; Alexandra Johnson; Stam Kapetanakis; Lisa Kuhwald; Adrian Morley-Davies; Ros Quinlivan; Konstantinos Savvatis; Marianela Schiava; Zaheer Yousef; Michela Guglieri Journal: Open Heart Date: 2022-10
Authors: Kan N Hor; Janaka P Wansapura; Hussein R Al-Khalidi; William M Gottliebson; Michael D Taylor; Richard J Czosek; Sherif F Nagueh; Nandakishore Akula; Eugene S Chung; Woodrow D Benson; Wojciech Mazur Journal: J Cardiovasc Magn Reson Date: 2011-02-02 Impact factor: 5.364